Stockwatch: GSK's Insurgent Discovery
This article was originally published in Scrip
Executive Summary
Last week GlaxoSmithKline Plc (GSK) and partner Theravance, Inc. announced the convincing failure of the long-anticipated SUMMIT study and although the share price of GSK only traded off about 1% on the first trading day after the announcement, the implications appear much further reaching than this minor share price drop would suggest, and not only for GSK.